Table 3.

Summary of outcomes: PE and major bleeding

Author, year	Comparison	PE						Major bleeding
		LMWH		Fondaparinux		Control		LMWH		Fondaparinux		Control
		Events	Total	Events	Total	Events	Total	Events	Total	Events	Total	Events	Total
Goel et al., 200928	LMWH vs placebo	0	127 (0%)	‐	‐	0	111 (0%)	0	127 (0%)	‐	‐	0	111 (0%)
Jørgensen et al., 200229	LMWH vs no treatment	0	99 (0%)	‐	‐	0	106 (0%)	0	99 (0%)	‐	‐	0	106 (0%)
Kock et al., 199530	LMWH vs no treatment	0	176 (0%)	‐	‐	0	163 (0%)	0	176 (0%)	‐	‐	0	163 (0%)
Kujath et al., 199331	LMWH vs no treatment	0	126 (0%)	‐	‐	0	127 (0%)	0	126 (0%)	‐	‐	0	127 (0%)
Lapidus et al., 2007a32	LMWH vs placebo	0	49 (0%)	‐	‐	0	47 (0%)	0	49 (0%)	‐	‐	0	47 (0%)
Lapidus et al., 2007b33	LMWH vs placebo	0	117 (0%)	‐	‐	0	109 (0%)	0	117 (0%)	‐	‐	0	109 (0%)
Lassen et al., 200234	LMWH vs placebo	0	183 (0%)	‐	‐	2	188 (1.1%)	2	217 (0.9%)	‐	‐	1	221 (0.5%)
Selby et al., 20158	LMWH vs placebo	0	130 (0%)	‐	‐	1	128 (0.8%)	0	134 (0%)	‐	‐	0	131 (0%)
van Adrichem et al., 2017 36	LMWH vs no treatment	4	719 (0.6%)	‐	‐	5	716 (0.7%)	0	719 (0%)	‐	‐	0	716 (0%)
Zheng et al., 20176	LMWH vs placebo	0	411 (0%)	‐	‐	0	403 (0%)	0	411 (0%)	‐	‐	0	403 (0%)
Gehling et al., 199827	LMWH vs aspirin	0	143 (0%)	‐	‐	0	144 (0%)	0	143 (0%)	‐	‐	0	144 (0%)
Bruntink et al., 20179	LMWH vs fondaparinux vs no treatment	0	92 (0%)	0	92 (0%)	2	94 (2.1%)	0	92 (0%)	0	92 (0%)	0	94 (0%)
Samama et al., 201335	LMWH vs fondaparinux	0	622 (0%)	2	621 (0.3%)	‐	‐	0	670 (0%)	1	674 (0.1%)	‐	‐

Abbreviations: DVT, deep vein thrombosis; LMWH, low molecular weight heparin; PE, pulmonary embolism.